IMPORTANCE Several recent US studies have documented racial disparities in head and neck cancer outcomes, but few have investigated racial and ethnic differences in salivary gland cancer (SGCA) survival.
a clinical and epidemiological challenge. In the past decade there has been increasing interest in the role that race and ethnicity play in cancer survival. Whereas several studies [2] [3] [4] have documented disparities in head and neck cancer outcomes for black patients in the United States, few studies have evaluated the effect that race and ethnicity have on disease-specific survival for patients with SGCA. We therefore conducted this study with the primary objective of determining whether racial and/or ethnic disparities exist for SGCA survival.
Methods

Data Source
Completely deidentified data for all cases of SGCA for the years 1988 to 2010 were acquired from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database on limited-use terms. Institutional review board review and informed consent were not required because the data were deidentified prior to our interaction with the data. The follow-up cutoff date for the November 2012 submission used in this analysis was December 31, 2010. The flowchart for the cohort selection is shown in Figure 1 . Patients whose diagnosis was made at death or autopsy and those with incomplete demographic information were excluded from the analysis. Patients were also excluded if the SGCA was not the patient's first cancer. Included primary sites as defined by the American Joint Committee on Cancer were identified by the following site codes: Parotid Gland (C079), Submandibular Gland (C080), Sublingual Gland (C081), Overlapping Lesion of Major Salivary Glands (C088), and Major Salivary Gland Not Otherwise Specified (C089). Histology codes were based on the SEER Histology Recode-Broad Groupings: epithelial, not otherwise specified (NOS) (01); squamous cell (02); adenomas and adenocarcinomas (05); mucoepidermoid neoplasms (07); cystic, mucinous, and serous (08); ductal and lobular (09); acinar cell (10) ; complex epithelial (11) ; complex mixed and stromal (21). Information for a unique patient identifier, sex, age at diagnosis, year of diagnosis, sequence number, tumor size, tumor extension, lymph node involvement, surgical treatment, radiation use and method, race, Hispanic ethnicity, survival time, cause of death, vital status at last follow-up, histologic subtype, grade, and source of report were extracted for each case. 
Data Analysis
Data extraction and preparation were performed in SAS, version 9.3 (SAS Institute). Patients were separated into 3 racial and/or ethnic groups as white, black, and Hispanic. Histologic groups were classified as mucoepidermoid carcinoma, adenocarcinoma, adenoid cystic carcinoma, squamous cell carcinoma, acinar cell carcinoma, and other malignant histologic subtypes. For tumor characteristics, tumor grade was reclassified as either low or high. The low-grade group included tumors reported as grade 1, grade 2, well differentiated, moderately differentiated, and with intermediate differentiation. The high-grade group included tumors reported as grade 3, grade 4, poorly differentiated, undifferentiated, and anaplastic. Extension was reclassified as intraglandular, extraglandular, or metastatic. Lymph node involvement was reclassified into either no lymph node involvement or positive nodes. In addition, for treatment characteristics, surgery and radiation therapy were dichotomized into yes or no. All statistical analyses and figure generation were performed in R and SAS, version 9.3. Comparisons of KaplanMeier survival estimates for white, black, and Hispanic populations were performed using the log-rank test, and confidence intervals (CIs) were calculated using the log-transform method. For further investigating the magnitude of disparity in survival between racial groups, Cox regression models were built to provide hazard ratios (HRs) with accompanying 95% CIs for minority (Hispanic or black) vs white by controlling for patient characteristics (model 2), patient and tumor characteristics (model 3), and patient, tumor, and treatment characteristics (model 4) for all histologic subtypes. When the number of events (death from SGCA) was adequate for analysis, a separate set of Cox regression models were built for each of the individual SGCA histologic subtypes. P < .05 was considered statistically significant.
Results
Overall, 11 007 patients met criteria for inclusion in the study. Of these, 8866 (80.55%), 1073 (9.75%), and 1068 (9.70%) were white, black, and Hispanic, respectively (see Table 1 ). In the white population, 59.26% of patients were male, compared with 48.09% and 48.88% in the black and Hispanic populations, respectively (P < .001). Notably, the mean age at diagnosis for whites was 62.57 years, compared with 53.01 and 52.34 years for blacks and Hispanics, respectively (P < .001). Mean tumor size (greatest dimension) at diagnosis for whites (29.17 mm) was smaller than in blacks (33.47 mm) and Hispanics (31.23 mm; P < .001). Examination of tumor grade revealed a larger proportion of high-grade tumors in whites (33.03%) than in blacks (24.31%) and Hispanics (20.69%; P < .001). Whites had the greatest proportion of patients with positive lymph nodes (32.06%), whereas blacks were intermediate (27.66%) and Hispanics had the least (24.58%; P < .001). eTables 1 through 5 (in Supplement) show how these characteristics are distributed for the individual SGCA histologic subtypes. For all SGCA histologic subtypes combined, unadjusted Kaplan-Meier 5-year survival rates for whites, blacks, and Hispanics were 83%, 84%, and 89%, respectively, and 78%, 79%, and 81%, respectively, for 20-year survival (Table 2 and Figure 2 ). The log-rank test was used to compare the unadjusted survival curves, revealing that blacks had no significant difference in diseasespecific survival compared with whites (P = .18), whereas Hispanics had significantly better disease-specific survival than whites (P = .003).
The multivariable Cox regression models provide further insight as to how patient, tumor, and treatment characteristics affect disease-specific survival in whites, blacks, and Hispanics for all SGCA histologic subtypes combined ( Table 3 ). The models were built starting with the crude, unadjusted model (model 1), then progressed to controlling for patient characteristics (age and sex; model 2), then to controlling for patient characteristics and tumor characteristics (histologic subtype, tumor grade, tumor size, extension, and lymph node status; model 3), and finally to controlling for patient characteristics, tumor characteristics, and treatment characteristics (surgery and radiation; model 4). For all SGCA histologic subtypes, the unadjusted Cox model (model 1) showed the same results as the unadjusted Kaplan-Meier estimates: no significant difference in disease-specific survival for blacks compared with whites (HR, 0.97; P = .74) but an apparent survival advantage for Hispanics compared with whites (HR, 0.70; P = .001). However, when patient age and sex were controlled for (model 2), there was no significant difference in disease-specific survival for Hispanics compared with whites (HR, 0.97; P = .76), and a statistically significant worse disease-specific survival for blacks compared with whites (HR, 1.34; P = .001) was revealed. Controlling for tumor characteristics in addition to patient characteristics (model 3) and for patient, tumor, and treatment characteristics (model 4) yielded similar results to model 2: no significant difference in disease-specific survival between Hispanic and white patients but a statistically significant worse disease-specific survival for black compared with white patients (Table 3 ). In addition, older age at diagnosis, higher tumor grade, larger tumor size, extraglandular or metastatic extension, positive lymph nodes, and no surgical treatment each had a statistically significant detriment on survival for all patients.
We next analyzed the survival data by individual SGCA histologic subtypes. For patients with mucoepidermoid carcinoma, unadjusted Kaplan-Meier 5-year survival rates for whites, blacks, and Hispanics were 89%, 88%, and 95%, respectively, and 87%, 88%, and 93%, respectively, for 20-year survival (Table 2 and Figure 2 ). Using the log-rank test to compare the unadjusted survival curves, blacks had no significant difference in disease-specific survival compared with whites (P = .35), whereas Hispanics had significantly better disease-specific survival than whites (P = .02). The unadjusted Cox model (eTable 6 in Supplement, model 1) for mucoepidermoid carcinoma also showed no significant difference in disease-specific survival between black and white patients and an apparent survival advantage for Hispanic compared with white patients. Controlling for patient age and sex (model 2) showed no significant difference in disease-specific survival for black compared with white patients and eliminated the apparent survival advantage for Hispanic compared with white patients. However, in model 2 (patient characteristics) and model 3 (patient and tumor characteristics), black patients had statistically insignificant Copyright 2014 American Medical Association. All rights reserved.
poorer disease-specific survival compared with white patients. As the analysis progressed to the point of controlling for patient, tumor, and treatment characteristics (model 4), in comparison with white patients, there remained no statistical difference in disease-specific survival for Hispanic patients (HR, 0.76; P = .36), but black patients had statistically significant worse survival (HR, 1.56; P = .03).
For patients with adenocarcinoma, unadjusted KaplanMeier 5-year survival rates for whites, blacks, and Hispanics were 74%, 74%, and 81%, respectively, and 67%, 69%, and 77%, respectively, for 15-year survival ( Figure 2 and Table 2 ). There were an insufficient number of cases to calculate reliable 20-year survival rates for black or Hispanic patients.
When the log-rank test was used to compare the unadjusted survival curves, there was no statistically significant difference in disease-specific survival between black and white patients (P = .82) or Hispanic and white patients (P = .36). The multivariable Cox regression analysis presented in eTable 7 (in Supplement) shows that when patient, tumor, and treatment characteristics were controlled for, there remained no statistically significant difference in diseasespecific survival for Hispanic compared with white patients (HR, 0.88; P = .58) or black compared with white patients (HR, 1.15; P = .45).
For patients with adenoid cystic carcinoma, unadjusted Kaplan-Meier 5-year survival rates for whites, blacks, and Hispanics were 89%, 91%, and 89%, respectively, and 75%, 72%, and 76%, respectively, for 20-year survival (Table 2 and Figure 2 ). There was no statistically significant difference in disease-specific survival between black and white patients (P > .99) or Hispanic and white patients (P = .99). The multivariable Cox regression analysis presented in eTable 8 (in Supplement) shows that when patient, tumor, and treatment characteristics were controlled for, there remained no statistically significant difference in disease-specific survival for Hispanic compared with white patients (HR, 1.05; P = .86) or black compared with white patients (HR, 1.15; P = .59).
For patients with squamous cell carcinoma, unadjusted Kaplan-Meier 5-year survival rates for whites, blacks, and Hispanics were 81%, 70%, and 76%, respectively, and 79%, 70%, and 69%, respectively, for 15-year survival ( Figure 2 and Table 2 ). There were an insufficient number of cases to calculate reliable 20-year survival rates for Hispanic patients. When the log-rank test was used to compare the unadjusted survival curves, there was no statistically significant difference in survival between black and white patients (P = .09) or Hispanic and white patients (P = .35). However, the unadjusted Cox model (eTable 9 in Supplement, model 1) for squamous cell carcinoma showed no significant difference in disease-specific survival between Hispanic and white patients but a statistically significant worse disease-specific survival for black compared with white patients. As the analysis progressed through the Cox models to control for patient characteristics (model 2), patient and tumor characteristics (model 3), and patient, tumor, and treatment characteristics (model 4), the results of equivalent diseasespecific survival for Hispanic and white patients but statistically significant worse disease-specific survival for black compared with white patients were maintained, although in model 4, the result for black compared with white patients became statistically nonsignificant (HR, 1.58; P = .05).
For patients with acinar cell carcinoma, unadjusted Kaplan-Meier 5-year survival rates for whites, blacks, and Hispanics were 95%, 97%, and 99%, respectively, and 91%, 94%, and 92%, respectively, for 20-year survival (Table 2 and Figure 2 ). When the log-rank test was used to compare the unadjusted survival curves, blacks had no significant difference in disease-specific survival compared with whites (P = .13), whereas Hispanics had statistically significant better disease-specific survival than whites (P = .049). When multivariable Cox regression modeling was attempted for this histologic subgroup, because of the high survival rates for all patient groups, the proportion of censoring was as high as 93% and the standard error on the parameter estimates was too wide, which raised concern for the validity of Abbreviations: Ellipses, reference group for each comparison; NR, not reported because of insufficient data. a P values for multiple comparisons of the log-rank test were based on the Tukey-Kramer adjustment.
Discussion
Significant disparities in survival have been demonstrated for black patients with cancers of the head and neck within the past decade. [2] [3] [4] [5] Molina and colleagues 2 found that for all locations of squamous cell carcinoma of the head and neck, median survival time for black patients was significantly shorter (21 months) than for white patients (40 months; P < .001). Likewise, Nichols and Bhattacharyya 3 demonstrated that for glottic squamous cell carcinoma, both mean overall survival and disease-specific survival were significantly worse in black patients compared with matched white controls. The authors of these studies found that a large portion of the disparity in survival for black patients is explained by more advanced disease at presentation, poorer socioeconomic status, comorbidities, and less surgical treatment. 2, 3 However, even when these variables are controlled for, poorer survival persisted in the black populations, leading the authors to speculate that other environmental, and perhaps genetic, factors play a role in the survival disparity.
2,3
Although numerous studies [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] in the literature have evaluated prognostic factors in SGCA survival, few 6, 14, 15 have evaluated the role that race and ethnicity play in survival in these cancers. In 1984, Spitz and Batsakis 6 noted improved overall survival for black patients compared with white patients in their study of 498 patients with SGCA from their institution; however, this finding was not subjected to multivariate analysis; in addition, no meaningful comparisons of survival could be made for Hispanic patients because only 7 of the 498 patients were Hispanic. In 2011, Cheung and colleagues 14 found that race and ethnicity had no effect (as determined by multivariable Cox regression analysis) on overall survival in a study of 968 patients with SGCA from a Florida cancer registry; this study included Hispanic patients and data on individual patient comorbidities. In 2012, Ellington and colleagues 15 studied incidence and survival trends for adenoid cystic SGCA in 3026 patients from the SEER database from 1973 to 2007; multivariable Cox regression models showed that race (defined as white, black, or other) had no effect on observed survival; ethnicity was not addressed in the study. Given the sparse literature on the topic, we conducted this study to determine whether racial and/or ethnic disparities exist for SGCA survival. To our knowledge, this is the when all SGCA histologic subtypes are examined together, our results show that there is an apparent survival advantage in SGCA for Hispanic patients compared with white Abbreviation: HR, hazard ratio. a In Cox regression analysis, only patients with complete treatment characteristics were considered (n = 10 745). Age at diagnosis and tumor size (greatest dimension) were divided into quartiles. For age at diagnosis, the upper limit of the second quartile, 62, was replaced by 65. Except for model 1 (crude model), diagnosis year was included into the models (not shown). b When the Cox regression models were fitted, the assumption of proportionality was assessed by the significance of a term of the predictor associated with the logarithm of survival time, and an appropriate stratified analysis was adopted if needed. In model 2 (patient characteristics) and model 3 (patient and tumor characteristics), there were no violations of this assumption. In model 4 (patient, tumor, and treatment characteristics), a severe violation appeared on radiotherapy (yes/no) and a stratified Cox model on radiotherapy was built; therefore, although not shown, radiotherapy is included in model 4. c For the analyses for all models with the same number of patients, the patients with unknown tumor grade, tumor size, extension, or lymph nodes were included.
patients that is explained entirely by younger age at diagnosis, whereas for black patients compared with white patients, there is an underlying statistically significant worse survival for SGCA that is revealed by controlling for patient characteristics (age and sex) and maintained when tumor and treatment characteristics are additionally controlled for (Table 3) . Looking more closely at the survival data for the individual SGCA histologic subtypes ( Table 2 , eTables 6-9 in Supplement), we see that this disparity is driven by poorer diseasespecific survival for black patients with mucoepidermoid (eTable 6 in Supplement) and squamous cell (eTable 9 in Supplement) carcinomas. However, the nature of the disparity differs between these 2 SGCA subtypes. For mucoepidermoid carcinoma, whereas statistically insignificant results showing worse disease-specific survival were noted as patient and patient and tumor variables were controlled for (eTable 6 in Supplement, models 2 and 3), a statistically significant poorer disease-specific survival for black patients was not observed until patient, tumor, and treatment variables (surgery and radiation, model 4) were controlled for, indicating that the poorer survival for black compared with white patients with mucoepidermoid carcinoma is due to other variables that were not controlled for. This is in contradistinction to the pattern that we see for squamous cell carcinoma, in which the unadjusted Cox model (eTable 9 in Supplement, model 1) shows a baseline statistically significant poorer disease-specific survival for black compared with white patients. As we progress through the Cox models for squamous cell carcinoma, controlling for patient, tumor, and treatment variables, this poorer disease-specific survival for black compared with white patients is maintained until treatment variables are added (surgery and radiation, model 4). At this point, the difference in disease-specific survival becomes statistically nonsignificant, implying that the poorer survival for black compared with white patients with squamous cell carcinoma is largely due to differences in treatment regimens between the 2 groups. As shown in eTable 4 (in Supplement), the difference is that black patients received significantly less surgical treatment than white patients (57.26% vs 76.94%; P < .001); this finding is consistent with several previously published studies on racial disparities in survival from squamous cell carcinoma of the head and neck. [2] [3] [4] However, it remains possible that other factors beyond those that we controlled for contributed to the observed survival disparity.
The recent study by Cheung and colleagues 14 provides additional insight into possible sources of the poorer diseasespecific survival for black patients demonstrated in our study. The data set in their study was obtained from the Florida Cancer Data System, which contains chemotherapy data in addition to surgery and radiation treatment data; in their study, the Florida Cancer Data System was also linked to the Florida Agency for Health Care Administration to obtain data on patient comorbidities and, ultimately, through the US Census Bureau, data on community poverty levels for the patients. Therefore, whereas Cheung and colleagues 14 found that race and ethnicity had no effect on survival, unlike our study, they were able to control for patient comorbidities, poverty level, and chemotherapy treatment, which implies that the source of survival disparity for black patients compared with white patients seen in our study could be due to differences in chemotherapy treatment, comorbidities, and/or poverty levels. Whereas this comparison is helpful for potentially directing future research, it is not conclusive because their study and ours are not directly comparabletheir study evaluated overall survival whereas ours evaluated disease-specific survival, a key distinction. It would be expected that comorbidities would have a greater impact on overall survival than on disease-specific survival, with an important exception being those cases in which the presence of certain comorbidities influenced treatment decisions, which would then allow comorbidities to indirectly influence disease-specific survival. The larger data set in our study also provides increased power to detect smaller differences.
Tumor genetic factors are another potential source for the poorer disease-specific survival for black compared with white patients in our study. Within the last 2 years, it has been shown that overexpression and increased gene copy number of EGFR and HER2 are correlated with high tumor grade and unfavorable survival for patients with SGCA. 16, 17 In addition, gain or loss of MET gene copies and PTEN deletions correlate strongly with high tumor grade, increased rate of lymph node metastases, and poorer overall survival in SGCA. 18, 19 PTEN deletions are also strongly correlated with increased EGFR and HER2 expression and are potentially responsible for the poor response that has been observed when anti-EGFR and anti-HER2 therapies are used to treat patients with SGCA who have increased EGFR and HER2 expression. 19 We have previously shown that the disparity in survival for black compared with white patients with squamous cell carcinoma of the head and neck can be explained entirely by a greater proportion of human papillomavirus-negative disease in the oropharynx for black compared with white patients. 5 It is therefore tempting to speculate that genetic variations in EGFR, HER2, MET, and PTEN in SGCA between black and white populations could explain at least some of the survival disparities that we observed in the present study; additional research is warranted in this area. Finally, environmental exposures are also a possible source for the poorer disease-specific survival for black patients in our study. Looking at differences in occupational exposures between black and white patients with SGCA, Wilson and colleagues 20 
